Investigation of the sero-epidemiology of vaccine preventable diseases and common viral infections in French populations using a multiplex serological assay
Bloch, E.; Baudemont, G.; Donnadieu, F.; Garcia, L.; Pelleau, S.; SeroPed Study Consortium, ; Milieu Interieur Consortium, ; Quintana-Murci, L.; Duffy, D.; Fontanet, A.; White, M.
Show abstract
Vaccine-preventable diseases (VPDs) and common viral infections (CVIs) pose substantial public health challenges. Despite data collected through routine vaccination programs and through hospital-based case reporting systems, the understanding of population-level immunity to VPDs and CVIs remains limited. To address this challenge, this study focuses on the development and application of a high-throughput multiplex serological assay to assess IgG levels against a large panel of eight VPDs (e.g., tetanus, diphtheria, measles, mumps, rubella) and 18 CVIs that typically occur in early childhood (e.g., adenovirus, cytomegalovirus, respiratory syncytial virus). A cross-sectional study of 2,032 serum samples from French children and adults was used to optimize and validate a 47-plex assay. These antibody measurements allowed us to enhance our understanding of immunity, vaccination and booster dose effect, as well as antibody waning over time. Preliminary results demonstrate the importance of age-stratified IgG level measurements, revealing notable variation in seroprevalence patterns among different age groups. These findings suggest that there are variations in immunity and exposure to the targeted pathogens across these groups. These findings highlight the potential of high-throughput multiplex serology assays for routine surveillance of common viral infections and assessment of vaccine coverage.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Detection of neutralizing antibodies against SARS-CoV-2 by using a commercial surrogate virus neutralization ELISA: can it substitute the classical neutralization test? 96%
- Reduced serum neutralization capacity against SARS-CoV-2 variants in a multiplex ACE2 RBD competition assay 94%
- Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays 94%
Similar papers in this journal
- Serological assessment of SARS-CoV-2 exposure in northern Sweden by the use of at-home sampling to meet geographical challenges in rural regions 94%
- Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study 93%
- Higher risk of SARS-CoV-2 Omicron BA.4/5 infection than of BA.2 infection after previous BA.1 infection, the Netherlands, 2 May to 24 July 2022 92%
Similar papers in this journal
- A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2 95%
- Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2 94%
- Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity 93%
Similar papers in this journal
- Antibody Conversion rates to SARS-CoV-2 in Saliva from Children Attending Summer Schools in Barcelona, Spain 93%
- Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections 93%
- Human serum from SARS-CoV-2 vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant in comparison to the original Wuhan strain and the Beta and Delta variants 92%
Similar papers in this journal
- Towards Internationally standardised humoral Immune Correlates of Protection from SARS-CoV-2 infection and COVID-19 disease 96%
- Multiplex Antibody Analysis of IgM, IgA and IgG to SARS-CoV-2 in Saliva and Serum from Infected Children and their Close Contacts 95%
- Clinical utility of Elecsys Anti-SARS-CoV-2 S assay in COVID-19 vaccination: An exploratory analysis of the mRNA-1273 phase 1 trial 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.